190 related articles for article (PubMed ID: 34181413)
1. Nanostructured Valsartan Microparticles with Enhanced Bioavailability Produced by High-Throughput Electrohydrodynamic Room-Temperature Atomization.
Prieto C; Evtoski Z; Pardo-Figuerez M; Hrakovsky J; Lagaron JM
Mol Pharm; 2021 Aug; 18(8):2947-2958. PubMed ID: 34181413
[TBL] [Abstract][Full Text] [Related]
2. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
[TBL] [Abstract][Full Text] [Related]
3. Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan.
Chella N; Daravath B; Kumar D; Tadikonda RR
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):517-26. PubMed ID: 26156887
[TBL] [Abstract][Full Text] [Related]
4. Melt dispersion granules: formulation and evaluation to improve oral delivery of poorly soluble drugs - a case study with valsartan.
Chella N; Tadikonda R
Drug Dev Ind Pharm; 2015 Jun; 41(6):888-97. PubMed ID: 24796274
[TBL] [Abstract][Full Text] [Related]
5. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization.
Hörmann TR; Jäger N; Funke A; Mürb RK; Khinast JG; Paudel A
Int J Pharm; 2018 Dec; 553(1-2):408-421. PubMed ID: 30326284
[TBL] [Abstract][Full Text] [Related]
6. Development of self-nanoemulsifying drug delivery system for oral bioavailability enhancement of valsartan in beagle dogs.
Li Z; Zhang W; Gao Y; Xiang R; Liu Y; Hu M; Zhou M; Liu X; Wang Y; He Z; Sun Y; Sun J
Drug Deliv Transl Res; 2017 Feb; 7(1):100-110. PubMed ID: 27812915
[TBL] [Abstract][Full Text] [Related]
7. Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers.
Beg S; Swain S; Singh HP; Patra ChN; Rao ME
AAPS PharmSciTech; 2012 Dec; 13(4):1416-27. PubMed ID: 23070560
[TBL] [Abstract][Full Text] [Related]
8. Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan.
Biswas N
Eur J Pharm Sci; 2017 Mar; 99():152-160. PubMed ID: 27993684
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Evaluation of Improved Oral Bioavailability of Valsartan: Proliposomes Versus Self-Nanoemulsifying Drug Delivery System.
Nekkanti V; Wang Z; Betageri GV
AAPS PharmSciTech; 2016 Aug; 17(4):851-62. PubMed ID: 26381913
[TBL] [Abstract][Full Text] [Related]
10. Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer.
Li DX; Yan YD; Oh DH; Yang KY; Seo YG; Kim JO; Kim YI; Yong CS; Choi HG
Drug Deliv; 2010 Jul; 17(5):322-9. PubMed ID: 20367177
[TBL] [Abstract][Full Text] [Related]
11. Carrier particle mediated stabilization and isolation of valsartan nanoparticles.
Kumar A; Davern P; Hodnett BK; Hudson SP
Colloids Surf B Biointerfaces; 2019 Mar; 175():554-563. PubMed ID: 30579056
[TBL] [Abstract][Full Text] [Related]
12. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
13. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S; Reddy VA; Arora S; Patel K
Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
[TBL] [Abstract][Full Text] [Related]
14. DEVELOPMENT OF SOLID LIPID NANOCARRIERS FOR ORAL DELIVERY OF CANDESERTAN CILEXETIL.
Ugurlu T; Nalbantoglu A; Sengel-Turk CT
Acta Pol Pharm; 2016 Nov; 73(6):1631-1638. PubMed ID: 29634119
[TBL] [Abstract][Full Text] [Related]
15. Novel nanocrystal-based solid dispersion with high drug loading, enhanced dissolution, and bioavailability of andrographolide.
Ma Y; Yang Y; Xie J; Xu J; Yue P; Yang M
Int J Nanomedicine; 2018; 13():3763-3779. PubMed ID: 29988798
[TBL] [Abstract][Full Text] [Related]
16. Application of Central Composite Design in Optimization of Valsartan Nanosuspension to Enhance its Solubility and Stability.
Vuppalapati L; Cherukuri S; Neeli V; Yeragamreddy PR; Kesavan BR
Curr Drug Deliv; 2016; 13(1):143-57. PubMed ID: 26205900
[TBL] [Abstract][Full Text] [Related]
17. Sustainable Stabilizer-Free Nanoparticle Formulations of Valsartan Using Eudragit
Hajba-Horváth E; Fodor-Kardos A; Shah N; Wacker MG; Feczkó T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884873
[TBL] [Abstract][Full Text] [Related]
18. Development and optimization of press coated tablets of release engineered valsartan for pulsatile delivery.
Shah S; Patel R; Soniwala M; Chavda J
Drug Dev Ind Pharm; 2015; 41(11):1835-46. PubMed ID: 25721985
[TBL] [Abstract][Full Text] [Related]
19. Fabrication and evaluation of valsartan-polymer- surfactant composite nanoparticles by using the supercritical antisolvent process.
Kim MS; Baek IH
Int J Nanomedicine; 2014; 9():5167-76. PubMed ID: 25404856
[TBL] [Abstract][Full Text] [Related]
20. Influence of Hydroxypropyl Methylcellulose on Metronidazole Crystallinity in Spray-Congealed Polyethylene Glycol Microparticles and Its Impact with Various Additives on Metronidazole Release.
Oh CM; Heng PW; Chan LW
AAPS PharmSciTech; 2015 Dec; 16(6):1357-67. PubMed ID: 25933626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
